Continuous versus intermittent therapy for moderate-to-severe psoriasis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Ramirez Fort, Marigdalia K ^a   Levin, Adriane A ^a   Au, Shiu Chung ^a   Gottlieb, Alice B ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic agents; Intermittent therapy; Psoriasis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PLACEBO; USTEKINUMAB;

ABNORMAL LABORATORY RESULT; ARTICLE; CANCER RISK; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; EXCIMER LASER; HUMAN; INFECTION; INFUSION RELATED REACTION; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PUVA; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; ULTRAVIOLET B RADIATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885802405     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. PERRY HO, SODERSTROM CW, SCHULZE RW: The Goeckerman treatment of psoriasis. Arch Dermatol 1968; 98: 178-82.
2. MULLER SA, PERRY HO: The Goeckerman treatment in psoriasis: six decades of experience at the Mayo Clinic. Cutis 1984; 34: 265-268+270.
3. PARRISH JA, FITZPATRICK TB, TANENBAUM L, PATHAK MA: Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. New Engl J Med 1974; 291: 1207-11.
4. MUELLER W, HERRMANN B: Cyclosporin A for psoriasis. New Engl J Med 1979; 301: 555.
5. KALB RE, STROBER B, WEINSTEIN G, LEBWOHL M: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
6. MENTER A, KORMAN NJ, ELMETS CA et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
7. WEINSTEIN GD, WHITE GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-59.
8. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90.
9. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: twoyear radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
10. SAURAT JH, STINGL G, DUBERTRET L et al.: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
11. GOTTLIEB A, KORMAN NJ, GORDON KB et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851-64.
12. REICH K, SIGNOROVITCH J, RAMAKRISHNAN K et al.: Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 2010; 63: 1011-8.
13. CASTELO-SOCCIO L, Van VOORHEES AS: Long-term efficacy of biologics in dermatology. Dermatol Ther 2009; 22: 22-33.
14. MENTER A, FELDMAN SR, WEINSTEIN GD et al.: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31 e31-15.
15. REICH K, WOZEL G, ZHENG H, van HOOGSTRATEN HJ, FLINT L, BARKER J: Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate- to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013; 168: 1325-34.
16. KOO J, LEBWOHL M: Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-9.
17. KARAKAWA M, KOMINE M, TAKEKOSHI T et al.: Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris. J Dermatol 2011; 38: 655-60.
18. LEBWOHL M, ALI S: Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98; quiz 499-502.
19. MENTER A, KORMAN NJ, ELMETS CA et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-35.
20. STAIDLE JP, DABADE TS, FELDMAN SR: A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011; 12: 2041-54.
21. YENTZER BA, YELVERTON CB, SIMPSON GL et al.: Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J 2009; 15: 1.
22. LEVER LR, FARR PM: Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-9.
23. STERN RS, NICHOLS KT, VAKEVA LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041-5.
24. STERN RS, LAIRD N, MELSKI J, PARRISH JA, FITZPATRICK TB, BLEICH HL: Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-61.
25. STERN RS, LANGE R: Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
26. LINDELOF B, SIGURGEIRSSON B, TEGNER E et al.: PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-3.
27. STERN RS, LIEBMAN EJ, VAKEVA L: Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-84.
28. STERN RS, LAIRD N: The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994; 73: 2759-64.
29. MAN I, CROMBIE IK, DAWE RS, IBBOTSON SH, FERGUSON J: The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005; 152: 755-7.
30. HEARN RM, KERR AC, RAHIM KF, FERGUSON J, DAWE RS: Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159: 931-5.
31. van de KERKHOF PC, de HOOP D, de KORTE J, COBELENS SA, KUIPERS MV: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-8.
32. NOLAN BV, FELDMAN SR: Dermatologic medication adherence. Dermatol Clin 2009; 27: 113-120, v.
33. TAN X, FELDMAN SR, CHANG J, BALKRISHNAN R: Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv 2012; 9: 1263-71.
34. MASON AR, MASON J, CORK M, DOOLEY G, HANCOCK H: Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; 3: CD005028.
35. BROWN KK, REHMUS WE, KIMBALL AB: Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-13.
36. CHARMAN CR, MORRIS AD, WILLIAMS HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6.
37. SAMARASEKERA EJ, SAWYER L, WONDERLING D, TUCKER R, SMITH CH: Topical therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol 2013;168: 954-67.
38. LIEM WH, McCULLOUGH JL, WEINSTEIN GD: Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995; 55: 306-10.
39. ZAGHLOUL SS, GOODFIELD MJ: Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-14.
40. RICHARDS HL, FORTUNE DG, O'SULLIVAN TM, MAIN CJ, GRIFFITHS CE: Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-3.
41. STORM A, ANDERSEN SE, BENFELDT E, SERUP J: One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008; 59: 27-33.
42. CLARK AR, FELDMAN SR: Intermittent, short term use of methotrexate for exacerbations of psoriasis. Int J Dermatol 1997; 36: 954-5.
43. BAKER H: Intermittent high dose oral methotrexate therapy in psoriasis. Br J Dermatol 1970; 82: 65-9.
44. KUMAR B, HANDA S, KAUR I: Short term methotrexate therapy in psoriasis. Indian J Med Res 1994;100: 277-80.
45. KUMAR B, SARASWAT A, KAUR I: Shortterm methotrexate therapy in psoriasis: a study of 197 patients. Int J Dermatol 2002; 41: 444-8.
46. SANDHU K, KAUR I, KUMAR B, SARASWAT A: Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458-63.
47. DOGRA S, KRISHNA V, KANWAR AJ: Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 2012; 37: 729-34.
48. MAHBUB MS, KHONDKER L, KHAN SI, HAZRA SC: Comparative efficacy of hydroxyurea and methotrexate in treating psoriasis. Mymensingh Med J 2013; 22: 116-30.
49. NYFORS A, BRODTHAGEN H: Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970; 140: 345-55.
50. CARNEIRO SC, CASSIA FF, LAMY F, CHAGAS VL, RAMOS-e-SILVA M: Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages. J Eur Acad Dermatol Venereol 2008; 22: 25-9.
51. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64: 207-11.
52. HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.
53. HAUSTEIN UF, RYTTER M: Methotrexate in psoriasis: 26 years' experience with lowdose long-term treatment. J Eur Acad Dermatol Venereol 2000; 14: 382-8.
54. van DOOREN-GREEBE RJ, KUIJPERS AL, TERMORSHUIZEN F, van de KERKHOF PC: Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995; 75: 393-6.
55. RITCHLIN CT, KAVANAUGH A, GLADMAN DD et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
56. ELLIS CN, GORSULOWSKY DC, HAMILTON TA et al.: Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-6.
57. GRIFFITHS CE, POWLES AV, LEONARD JN, FRY L, BAKER BS, VALDIMARSSON H: Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986; 293: 731-2.
58. GRIFFITHS CE, DUBERTRET L, ELLIS CN et al.: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150 (Suppl. 67): 11-23.
59. HO VC: The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004; 150: 1-10.
60. HO VC, GRIFFITHS CE, BERTH-JONES J et al.: Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-51.
61. OHTSUKI M, NAKAGAWA H, SUGAI J et al.: Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol 2003; 30: 290-8.
62. CHAIDEMENOS GC, MOURELLOU O, AVGOUSTINAKI N, PAPAKONSTANTINOU M, KARAKATSANIS G, KATSAMBAS A: Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 1203-8.
63. POWLES AV, HARDMAN CM, PORTER WM, COOK T, HULME B, FRY L: Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-9.
64. MONTAUDIE H, SBIDIAN E, PAUL C et al.: Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 2): 12-8.
65. THACI D, BRAUTIGAM M, KAUFMANN R, WEIDINGER G, PAUL C, CHRISTOPHERS E: Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002; 205: 383-8.
66. ABE M, SYUTO T, HASEGAWA M, SOGABE Y, YOKOYAMA Y, ISHIKAWA O: Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris. J Dermatol 2006; 33: 108-11.
67. BAGOT M, GROSSMAN R, PAMPHILE R et al.: Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis. C R Acad Sci III 1994; 317: 282-6.
68. GROSSMAN RM, THIVOLET J, CLAUDY A et al.: A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68-74.
69. KOKELJ F, TORSELLO P, PLOZZER C: Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998; 10: 143-6.
70. GROSSMAN RM, CHEVRET S, ABI-RACHED J, BLANCHET F, DUBERTRET L: Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623-9.
71. CORAZZA M, ZAMPINO MR, MONTANARI A, ALTIERI E, VIRGILI A: Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003; 206: 330-3.
72. FOZZA C, DORE F, BONFIGLI S, PODDA L, LONGINOTTI M: Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia. Eur J Dermatol 2005; 15: 271-3.
73. LAIN EL, MARKUS RF: Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol 2004; 3: 680-2.
74. LELIEVRE JD, SACRE K, ADLE-BIASSETTE H, MOLINIER-FRENKEL V, GAULARD P, PAPO T: Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol 2005; 52 (Suppl. 1): 24-7.
75. WATABE H, SOMA Y, OBARA W et al.: Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol 2006; 86: 184-5.
76. BEHNAM SM, BEHNAM SE, KOO JY: Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 2005; 4: 189-94.
77. PAUL CF, HO VC, McGEOWN C et al.: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. The J Invest Dermatol 2003; 120: 211-6.
78. MARCIL I, STERN RS: Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-5.
79. NIJSTEN TE, STERN RS: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-50.
80. DOGRA S, JAIN A, KANWAR AJ: Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol 2012 Jul 23 [Epub ahead of print].
81. HAUSHALTER K, MURAD EJ, DABADE TS, ROWELL R, PEARCE DJ, FELDMAN SR: Efficacy of low-dose acitretin in the treatment of psoriasis. J Dermatolog Treat 2012; 23: 400-3.
82. OLSEN EA, WEED WW, MEYER CJ, COBO LM: A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-6.
83. KATZ HI, WAALEN J, LEACH EE: Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12.
84. MOORE A, GORDON KB, KANG S et al.: A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
85. ORTONNE J-P, GRIFFITHS CEM, DAUDéN E et al.: Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol 2008; 3: 657-65.
86. GORDON KB, GOTTLIEB AB, LEONARDI CL et al.: Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9-17.
87. GELFAND JM, KIMBALL AB, MOSTOW EN et al.: Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11: 400-7.
88. ORTONNE JP, TAIEB A, ORMEROD AD et al.: Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009; 161: 1190-5.
89. BARRERA MV, HABICHEYN S, MENDIOLA MV, HERRERA CEBALLOS E: Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683-7.
90. SIEGFRIED EC, EICHENFIELD LF, PALLER AS, PARISER D, CREAMER K, KRICORIAN G: Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 2010; 63: 769-74.
91. ESPOSITO M, GIUNTA A, MAZZOTTA A et al.: Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312-9.
92. GORDON KB, LANGLEY RG, LEONARDI C et al.: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
93. PAPP K, CROWLEY J, ORTONNE JP et al.: Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-41.
94. MAHIL SK, ARKIR Z, RICHARDS G, LEWIS CM, BARKER JN, SMITH CH: Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single centre, cohort study. Br J Dermatol 2013; 169: 306-13.
95. LECLUSE LL, DRIESSEN RJ, SPULS PI et al.: Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.
96. MATSUMOTO Y, MAEDA T, TSUBOI R, OKUBO Y: Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40: 389-92.
97. LEE LY, SANDERSON JD, IRVING PM: Antiinfliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a metaanalysis. Eur J Gastroenterol Hepatol 2012; 24: 1078-85.
98. GOSPODAREVSKAYA E, PICOT J, COOPER K, LOVEMAN E, TAKEDA A: Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess 2009; 13 (Suppl. 3): 61-6.
99. KIMBALL AB, GORDON KB, FAKHARZADEH S et al.: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-72.
100. YEUNG H, WAN J, Van VOORHEES AS et al.: Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 64-72.
101. KAMANGAR F, ISIP L, BHUTANI T et al.: How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. J Dermatolog Treat 2013; 24: 13-24.
102. RAVAL K, LOFLAND JH, WATERS H, PIECH CT: Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol 2011; 10: 189-96.
103. JEVTIC T, BUKUMIRIC Z, S MJ: Effects of treatment adherence on clinical and economic outcomes in patients with psoriasis. Med Glas (Zenica) 2013; 10: 106-12.
104. THORNELOE RJ, BUNDY C, GRIFFITHS CE, ASHCROFT DM, CORDINGLEY L: Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol 2013; 168: 20-31.
105. GOKDEMIR G, ARI S, KOSLU A: Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330-5.
106. RENZI C, PICARDI A, ABENI D et al.: Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-42.
107. BUSTI AJ, HOOPER JS, AMAYA CJ, KAZI S: Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 2005; 25: 1566-91.
108. LEE RH, EFRON DT, TANTRY U et al.: Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen 2000; 8: 547-53.
109. MOONEY DP, O'REILLY M, GAMELLI RL: Tumor necrosis factor and wound healing. Ann Surg 1990; 211: 124-9.
110. BARRIENTOS S, STOJADINOVIC O, GOLINKO MS, BREM H, TOMIC-CANIC M: Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
111. COWIN AJ, HATZIRODOS N, RIGDEN J, FITRIDGE R, BELFORD DA: Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen 2006; 14: 421-6.
112. RAPALA K, LAATO M, NIINIKOSKI J et al.: Tumor necrosis factor alpha inhibits wound healing in the rat. Eur Surg Res 1991; 23: 261-8.
113. RAPALA KT, VAHA-KREULA MO, HEINO JJ, VUORIO EI, LAATO MK: Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia 1996; 52: 70-4.
114. SALOMON GD, KASID A, CROMACK DT et al.: The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 1991; 214: 175-80.
115. HESSION MT, GOTTLIEB AB: Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. J Dermatolog Treat 2011; 22: 90-101.
116. HELLER MM, WU JJ, MURASE JE: Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol 2011; 65: 870.
117. OSTENSEN M, FORGER F: How safe are anti- rheumatic drugs during pregnancy?. Curr Opin Pharmacol 2013; 13: 470-5.
118. CHAMBERS CD, JOHNSON DL: Emerging data on the use of anti-tumor necrosis factor- alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012; 94: 607-11.